Trastuzumab Deruxtecan
Phase 1Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Recurrent or Metastatic Solid Tumors
Conditions
Recurrent or Metastatic Solid Tumors
Trial Timeline
Jul 17, 2025 → Dec 31, 2028
NCT ID
NCT07015697About Trastuzumab Deruxtecan
Trastuzumab Deruxtecan is a phase 1 stage product being developed by Daiichi Sankyo for Recurrent or Metastatic Solid Tumors. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07015697. Target conditions include Recurrent or Metastatic Solid Tumors.
What happened to similar drugs?
6 of 20 similar drugs in Recurrent or Metastatic Solid Tumors were approved
Approved (6) Terminated (0) Active (14)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07015697 | Phase 1 | Recruiting |
| NCT06750484 | Phase 2 | Recruiting |
| NCT05982678 | Phase 2 | Recruiting |
| NCT06386263 | Pre-clinical | Completed |
| NCT06210776 | Pre-clinical | Recruiting |
| NCT05950945 | Phase 3 | Recruiting |
| NCT05993234 | Pre-clinical | Recruiting |
| NCT05945732 | Pre-clinical | Recruiting |
| NCT05458401 | Pre-clinical | Completed |
| NCT05246514 | Phase 2 | Active |
| NCT04989816 | Phase 2 | Completed |
| NCT04739761 | Phase 3 | Active |
| NCT04644237 | Phase 2 | Completed |
| NCT04639219 | Phase 2 | Active |
| NCT04482309 | Phase 2 | Recruiting |
| NCT04752059 | Phase 2 | Completed |
| NCT04420598 | Phase 2 | Completed |
| NCT04014075 | Phase 2 | Completed |
| NCT03505710 | Phase 2 | Terminated |
Competing Products
20 competing products in Recurrent or Metastatic Solid Tumors